Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
2 Apr 24
8-K
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
26 Mar 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
8-K
Biora Therapeutics Provides Outlook for 2024
16 Jan 24
8-K
Transaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company
18 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 23
8-K
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination
1 Dec 23
8-K
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Unregistered Sales of Equity Securities
13 Oct 23
8-K
Unregistered Sales of Equity Securities
11 Oct 23
Registration and prospectus
S-3
Shelf registration
8 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
S-3
Shelf registration
22 Dec 23
424B3
Prospectus supplement
10 Oct 23
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
9 Dec 22
DEF 14A
Definitive proxy
29 Nov 22
PRE 14A
Preliminary proxy
10 Nov 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
EFFECT
Notice of effectiveness
18 Apr 24
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
27 Dec 23
UPLOAD
Letter from SEC
26 Dec 23
EFFECT
Notice of effectiveness
8 Feb 23
CORRESP
Correspondence with SEC
3 Feb 23
UPLOAD
Letter from SEC
1 Feb 23
EFFECT
Notice of effectiveness
9 Aug 21
CORRESP
Correspondence with SEC
4 Aug 21
UPLOAD
Letter from SEC
3 Aug 21
Ownership
SC 13D/A
Athyrium Opportunities 2020 LP
2 Apr 24
4
Eric dEsparbes
15 Feb 24
4
CLARKE NEUMANN
15 Feb 24
4
ADITYA P. MOHANTY
15 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
Athyrium Opportunities 2020 LP
20 Dec 23
4
Jeffrey Ferrell
20 Dec 23
SC 13D/A
Athyrium Opportunities 2020 LP
19 Sep 23
4
Jeffrey Ferrell
19 Sep 23
4
CLARKE NEUMANN
17 Aug 23